GMAB Quote, Financials, Valuation and Earnings

Evaxion AS has a net margin of 39.24% compared to Genmab A/S's net margin of -64.14%. Genmab A/S's return on equity of 28.3% beat Evaxion AS's return on equity of --.

Genmab A/S has a consensus price target of $37.24, signalling upside risk potential of 16.31%. On the other hand Evaxion AS has an analysts' consensus of $14.18 which suggests that it could grow by 167.96%. Given that Evaxion AS has higher upside potential than Genmab A/S, analysts believe Evaxion AS is more attractive than Genmab A/S.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1B, which are larger than Evaxion AS quarterly revenues of $37.5K. Genmab A/S's net income of $399.2M is higher than Evaxion AS's net income of -$4.9M. Notably, Genmab A/S's price-to-earnings ratio is 13.60x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.61x versus 3.55x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

IO Biotech, Inc. has a net margin of 39.24% compared to Genmab A/S's net margin of --. Genmab A/S's return on equity of 28.3% beat IO Biotech, Inc.'s return on equity of -297.46%.

Genmab A/S has a consensus price target of $37.24, signalling upside risk potential of 16.31%. On the other hand IO Biotech, Inc. has an analysts' consensus of $2.46 which suggests that it could grow by 284.18%. Given that IO Biotech, Inc. has higher upside potential than Genmab A/S, analysts believe IO Biotech, Inc. is more attractive than Genmab A/S.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison IO Biotech, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IO Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. IO Biotech, Inc. pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1B, which are larger than IO Biotech, Inc. quarterly revenues of --. Genmab A/S's net income of $399.2M is higher than IO Biotech, Inc.'s net income of -$8.4M. Notably, Genmab A/S's price-to-earnings ratio is 13.60x while IO Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.61x versus -- for IO Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merus NV has a net margin of 39.24% compared to Genmab A/S's net margin of -786.17%. Genmab A/S's return on equity of 28.3% beat Merus NV's return on equity of -53.47%.

Genmab A/S has a consensus price target of $37.24, signalling upside risk potential of 16.31%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.92%. Given that Genmab A/S has higher upside potential than Merus NV, analysts believe Genmab A/S is more attractive than Merus NV.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1B, which are larger than Merus NV quarterly revenues of $12.2M. Genmab A/S's net income of $399.2M is higher than Merus NV's net income of -$95.5M. Notably, Genmab A/S's price-to-earnings ratio is 13.60x while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.61x versus 120.82x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of 39.24% compared to Genmab A/S's net margin of 26.68%. Genmab A/S's return on equity of 28.3% beat Novo Nordisk A/S's return on equity of 68.76%.

Genmab A/S has a consensus price target of $37.24, signalling upside risk potential of 16.31%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.05 which suggests that it could grow by 11.52%. Given that Genmab A/S has higher upside potential than Novo Nordisk A/S, analysts believe Genmab A/S is more attractive than Novo Nordisk A/S.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.994%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 3.63% to investors and pays a quarterly dividend of $0.58 per share. Genmab A/S pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genmab A/S quarterly revenues are $1B, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Genmab A/S's net income of $399.2M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Genmab A/S's price-to-earnings ratio is 13.60x while Novo Nordisk A/S's PE ratio is 13.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.61x versus 4.54x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.